Advertisement

Topics

Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis

2016-07-05 22:34:30 | BioPortfolio

Published on BioPortfolio: 2016-07-05T22:34:30-0400

Clinical Trials [37 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination

The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403...

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone. A secondary objectiv...

The Safety and Tolerability of Pirfenidone for BOS After HCT

This is a phase 2, open label, single center randomized clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopo...

Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer

RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in pa...

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 mg/d compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to as...

PubMed Articles [24 Associated PubMed Articles listed on BioPortfolio]

Pirfenidone Inhibits Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway.

BACKGROUND Hepatocellular carcinoma (HCC) is the most important cause of cancer-related deaths worldwide. Pirfenidone is an orally available small molecule with therapeutic potential for fibrotic dise...

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.

To analyze the efficacy and adverse events  (AEs) of pirfenidone in idiopathic pulmonary fibrosis (IPF) trials. Methods: MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for studies p...

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis a real-world observational study.

Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of mild-to-moderate disease sever...

Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF-β1/Smad/CTGF signaling pathway.

Radiation-induced intestinal fibrosis (RIF) is a chronic toxicity following radiation, and can be very difficult to treat. Pirfenidone is a promising anti-fibrotic agent that inhibits fibrosis progres...

Potential treatment for vocal fold scar with pirfenidone.

Pirfenidone (PFD) is a strong antifibrotic agent that has been clinically approved in Japan for idiopathic pulmonary fibrosis. We examined the antifibrotic effects of PFD on fibroblasts isolated from ...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial